Identification
NamePiritrexim
Accession NumberDB03695  (EXPT02259, DB12918)
TypeSmall Molecule
GroupsInvestigational
Description

Piritrexim has been used in trials studying the treatment of Bladder Cancer, Urethral Cancer, and Transitional Cell Cancer of the Renal Pelvis and Ureter.

Structure
Thumb
SynonymsNot Available
External IDs BW 301U / BW-301U
Product Ingredients
IngredientUNIICASInChI KeyDetails
Piritrexim isethionateV77I71FH72 79483-69-5IOEMETRLOWNXGW-UHFFFAOYSA-NDetails
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
CategoriesNot Available
UNIIMK2A783ZUT
CAS number72732-56-0
WeightAverage: 325.3651
Monoisotopic: 325.153874877
Chemical FormulaC17H19N5O2
InChI KeyVJXSSYDSOJBUAV-UHFFFAOYSA-N
InChI
InChI=1S/C17H19N5O2/c1-9-11(6-10-7-12(23-2)4-5-13(10)24-3)8-20-16-14(9)15(18)21-17(19)22-16/h4-5,7-8H,6H2,1-3H3,(H4,18,19,20,21,22)
IUPAC Name
6-[(2,5-dimethoxyphenyl)methyl]-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine
SMILES
COC1=CC(CC2=C(C)C3=C(N=C2)N=C(N)N=C3N)=C(OC)C=C1
Pharmacology
IndicationNot Available
Structured Indications Not Available
PharmacodynamicsNot Available
Mechanism of action
TargetKindPharmacological actionActionsOrganismUniProt ID
Dihydrofolate reductaseProteinunknownNot AvailableHumanP00374 details
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organismsNot Available
PathwaysNot Available
Pharmacogenomic Effects/ADRs Not Available
Interactions
Drug Interactions Not Available
Food InteractionsNot Available
References
Synthesis ReferenceNot Available
General ReferencesNot Available
External Links
ATC CodesNot Available
AHFS CodesNot Available
PDB Entries
FDA labelNot Available
MSDSNot Available
Clinical Trials
Clinical Trials
PhaseStatusPurposeConditionsCount
2CompletedTreatmentBladder Cancers / Transitional Cell Cancer of the Renal Pelvis and Ureter / Urethral Cancer1
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage formsNot Available
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental PropertiesNot Available
Predicted Properties
PropertyValueSource
Water Solubility0.064 mg/mLALOGPS
logP2.23ALOGPS
logP2.44ChemAxon
logS-3.7ALOGPS
pKa (Strongest Acidic)16.06ChemAxon
pKa (Strongest Basic)3.91ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count7ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area109.17 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity95.58 m3·mol-1ChemAxon
Polarizability34.37 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9946
Blood Brain Barrier+0.9531
Caco-2 permeable+0.6964
P-glycoprotein substrateNon-substrate0.5083
P-glycoprotein inhibitor INon-inhibitor0.6491
P-glycoprotein inhibitor IIInhibitor0.5249
Renal organic cation transporterNon-inhibitor0.7951
CYP450 2C9 substrateNon-substrate0.8532
CYP450 2D6 substrateNon-substrate0.8253
CYP450 3A4 substrateSubstrate0.5169
CYP450 1A2 substrateInhibitor0.5058
CYP450 2C9 inhibitorNon-inhibitor0.6163
CYP450 2D6 inhibitorNon-inhibitor0.6833
CYP450 2C19 inhibitorNon-inhibitor0.7365
CYP450 3A4 inhibitorNon-inhibitor0.6194
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.5758
Ames testAMES toxic0.588
CarcinogenicityNon-carcinogens0.9373
BiodegradationNot ready biodegradable0.9956
Rat acute toxicity2.4764 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8309
hERG inhibition (predictor II)Non-inhibitor0.6007
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
Taxonomy
DescriptionThis compound belongs to the class of chemical entities known as pyrido[2,3-d]pyrimidines. These are compounds containing the pyrido[2,3-d]pyrimidine ring system, which is a pyridopyrimidine isomer with three ring nitrogen atoms at the 1-, 3-, and 8- position.
KingdomChemical entities
Super ClassOrganic compounds
ClassOrganoheterocyclic compounds
Sub ClassPyridopyrimidines
Direct ParentPyrido[2,3-d]pyrimidines
Alternative ParentsDimethoxybenzenes / Phenoxy compounds / Anisoles / Methylpyridines / Aminopyrimidines and derivatives / Alkyl aryl ethers / Primary aromatic amines / Imidolactams / Heteroaromatic compounds / Azacyclic compounds
SubstituentsDimethoxybenzene / Pyrido[2,3-d]pyrimidine / P-dimethoxybenzene / Phenol ether / Phenoxy compound / Anisole / Methoxybenzene / Alkyl aryl ether / Aminopyrimidine / Methylpyridine
Molecular FrameworkAromatic heteropolycyclic compounds
External DescriptorsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Nadph binding
Specific Function:
Key enzyme in folate metabolism. Contributes to the de novo mitochondrial thymidylate biosynthesis pathway. Catalyzes an essential reaction for de novo glycine and purine synthesis, and for DNA precursor synthesis. Binds its own mRNA and that of DHFRL1.
Gene Name:
DHFR
Uniprot ID:
P00374
Molecular Weight:
21452.61 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235 ]
Drug created on June 13, 2005 07:24 / Updated on June 11, 2017 20:49